BRISTOL MYERS SQUIBB CO
BRISTOL MYERS SQUIBB CO (BMY): 135 pipeline candidates · 59 upcoming catalysts · ~11 mo cash runway · 181 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
10.9 months
D/E 3.31
Lead: Phase 3
135 candidates
59 upcoming, next in ~12d
0 buys · 2 sells (180d)
A transparent, data-derived signal for BRISTOL MYERS SQUIBB COacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$112.9B
Cash
$9.6B
Quarterly Burn
$4.3B
Runway
10.9 mo
Revenue
$11.5B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (135 candidates)
| Drug | Phase |
|---|---|
| afimetoran | Phase 2 |
| Alnuctamab | Phase 1 |
| approved hypertrophic cardiomyopathy drug treatments | — |
| Arlocabtagene Autoleucel | Phase 3 |
| BMS-813160 | Phase 4 |
| bms-936558-01 | Phase 1/Phase 2 |
| bms-986012 | Phase 4 |
| bms-986158 | Phase 4 |
| bms-986165 | Phase 4 |
| bms-986205 | Phase 4 |
Showing 10 of 135 candidates. Sign up for full pipeline.
Upcoming Catalysts (59)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2,517
Total value held
$97.90B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 264,640,480 | $16.05B |
| blackrock, inc. | 171,682,888 | $10.41B |
| state street corp | 98,564,914 | $5.98B |
| charles schwab investment management inc | 61,115,373 | $3.71B |
| geode capital management, llc | 55,286,174 | $3.34B |
| vanguard portfolio management llc | 46,230,155 | $2.80B |
| bank of america corp /de/ | 32,586,981 | $1.98B |
| aqr capital management llc | 29,631,105 | $1.80B |
| morgan stanley | 29,198,554 | $1.77B |
| ameriprise financial inc | 26,470,718 | $1.61B |
Showing top 10 of 2,517 institutional holders of BRISTOL MYERS SQUIBB CO. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BRISTOL MYERS SQUIBB CO's pipeline?
BRISTOL MYERS SQUIBB CO (BMY) has 135 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BRISTOL MYERS SQUIBB CO's lead drug candidate?
BRISTOL MYERS SQUIBB CO's most advanced tracked candidate is afimetoran (Phase 2) for Healthy Volunteers; Systemic Lupus Erythematosus.
What is BRISTOL MYERS SQUIBB CO's next catalyst?
BRISTOL MYERS SQUIBB CO's next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-Human, Single and Multiple Ascendi" — expected June 30, 2026.
What is BRISTOL MYERS SQUIBB CO's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BRISTOL MYERS SQUIBB CO has approximately 10.9 months of cash runway.
What is BRISTOL MYERS SQUIBB CO's market capitalization?
BRISTOL MYERS SQUIBB CO's market capitalization is approximately $112.9B.
Get the full picture on BRISTOL MYERS SQUIBB CO
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.